Denali Therapeutics Inc (DNLI)
Denali Therapeutics Inc. is a NASDAQ-listed biopharmaceutical company focused on developing therapies for neurodegenerative and lysosomal storage diseases. Its pipeline includes programs such as Eclitasertib (SAR443122/DNL758) for peripheral inflammatory diseases, BIIB122/DNL151 for Parkinson’s disease, TAK-594/DNL593 for frontotemporal dementia-granulin, DNL126 for MPS IIIA, and DNL310 Tividenofusp alfa for MPS II. The company also advances Enzyme TransportVehicle programs including DNL952 for Pompe disease, DNL111 for Parkinson’s and Gaucher diseases, and DNL622 for Hurler syndrome, along with OTV candidates such as DNL628 for Alzheimer’s disease and DNL422 for Parkinson’s disease. An antibody TV program, DNL921, targets Abeta in Alzheimer’s disease. Founded in 2013 and based in South San Francisco, California, the company was formerly known as SPR Pharma Inc. before adopting its current name in March 2015.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DNLI
|
$15.30
|
-34.8% Downside
|
Overvalued
|
$34.25
|
46.0% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-7.4x
|
4.0x
|
—
|
3.634 B
|
2.737 B
|
1.1%
|
90.9%
|
3.4
|
—
|
82.5%
|
